Atrion (NASDAQ:ATRI) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Atrion (NASDAQ:ATRI) in a report issued on Saturday morning. The firm issued a sell rating on the medical instruments supplier’s stock.

Atrion Trading Up 0.0 %

Atrion stock traded up $0.15 during mid-day trading on Friday, reaching $458.77. The company’s stock had a trading volume of 14,197 shares, compared to its average volume of 23,395. Atrion has a twelve month low of $274.98 and a twelve month high of $538.05. The business has a 50 day moving average price of $455.38 and a 200-day moving average price of $422.99. The firm has a market cap of $807.44 million, a price-to-earnings ratio of 43.12 and a beta of 0.69.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 EPS for the quarter. The business had revenue of $48.77 million during the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%.

Atrion Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Friday, June 14th were issued a $2.20 dividend. This represents a $8.80 annualized dividend and a dividend yield of 1.92%. The ex-dividend date was Friday, June 14th. Atrion’s dividend payout ratio (DPR) is 82.71%.

Institutional Investors Weigh In On Atrion

Several large investors have recently added to or reduced their stakes in ATRI. Versor Investments LP bought a new position in shares of Atrion during the second quarter worth about $3,247,000. Penn Mutual Asset Management LLC acquired a new stake in shares of Atrion in the fourth quarter valued at approximately $1,949,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Atrion in the first quarter valued at approximately $2,299,000. Citizens Financial Group Inc. RI bought a new stake in shares of Atrion during the fourth quarter valued at approximately $1,114,000. Finally, Wolverine Asset Management LLC acquired a new position in shares of Atrion during the second quarter worth approximately $624,000. 66.19% of the stock is owned by institutional investors and hedge funds.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.